A Phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies

Clinical Cancer Research

Volumn 8, Issue 12, 2002, Pages 3710-3717

  Rubin, Eric H ^a   De Alwis, Dinesh P ^c   Pouliquen, Isabelle ^c   Green, Lisa ^c   Marder, Phil ^c   Lin, Yong ^b   Musanti, Rita ^a   Grospe, Stephanie L ^a   Smith, Sharon L ^a   Toppmeyer, Deborah L ^a   Much, Judy ^a   Kane, Michael ^a   Chaudhary, Ajai ^c   Jordan, Christopher ^c   Burgess, Michael ^c   Slapak, Christopher A ^c  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN; ZOSUQUIDAR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; BRAIN DYSFUNCTION; BRAIN TOXICITY; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HALLUCINATION; HUMAN; LYMPHOCYTE; MALE; NATURAL KILLER CELL; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; TIME; TOXICITY;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CEREBELLAR DISEASES; DIBENZOCYCLOHEPTENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; P-GLYCOPROTEIN; QUINOLINES;

EID: 0036895024     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Litman, T., Druley, T. E., Stein, W. D., and Bates, S. E. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci., 58: 931-959, 2001.
2. Bosch, I., and Croop, J. P-glycoprotein multidrug resistance and cancer. Biochim. Biophys. Acta, 1288: F37-F54, 1996.
3. Ford, J. M., Yang, J. M., and Hait, W. N. P-glycoprotein-mediated multidrug resistance: Experimental and clinical strategies for its reversal. Cancer Treat. Res., 87: 3-38, 1996.
4. Sikic, B. I., Fisher, G. A., Lum, B. L., Halsey, J., Beketic-Oreskovic, L., and Chen, G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol., 40: S13-S19, 1997.
5. Sato, W., Fukazawa, N., Suzuki, T., Yusa, K., and Tsuruo, T. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res., 51: 2420-2424, 1991.
6. Dantzig, A. H., Shepard, R. L., Cao, J., Law, K. L., Ehlhardt, W. J., Baughman, T. M., Bumol, T. F., and Starling, J. J. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropy-Idibenzosuberane modulator, LY335979. Cancer Res., 56: 4171-4179, 1996.
7. Green, L. J., Marder, P., and Slapak, C. A. Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem. Pharmacol., 61: 1393-1399, 2001.
8. Reddy, V. R., Buben, J. A., Truex, L. L., Brown, D. E., Fletcher, D. J., Zimmerman, J. L., and Vahle, J. L. The toxicity and pharmacokinetic interaction of LY335979, an inhibitor of P-glycoprotein, with doxorubicin in beagle dogs. Proc. Am. Assoc. Cancer Res., 39: 512a, 1998.
9. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
10. Chaudhary, P. M., Mechetner, E. B., and Roninson, I. B. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood, 80: 2735-2739, 1992.
11. Klimecki, W. T., Futscher, B. W., Grogan, T. M., and Dalton, W. S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood, 83: 2451-2458, 1994.
12. Camaggi, C. M., Comparsi, R., Strocchi, E., Testoni, F., Angelelli, B., and Pannuti, F. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother. Pharmacol., 21: 221-228, 1988.
13. Boesch, D., Gaveriaux, C., Jachez, B., Pourtier-Manzanedo, A., Bollinger, P., and Loor, F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res., 51: 4226-4233, 1991.
14. Boote, D. J., Dennis, I. F., Twentyman, P. R., Osborne, R. J., Laburte, C., Hensel, S., Smyth, J. F., Brampton, M. H., and Bleehen, N. M. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol., 14: 610-618, 1996.
15. Giaccone, G., Linn, S. C., Welink, J., Catimel, G., Stieltjes, H., van der Vijgh, W. J., Eeltink, C., Vermorken, J. B., and Pinedo, H. M. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin. Cancer Res., 3: 2005-2015, 1997.
16. Greenberg, P., Advani, R., Tallman, M., Letendre, L., Saba, H., Dugan, K., Lee, S. J., Lum, B., Sikic, B. I., Paietta, E., Bennett, J., and Rowe, J. M. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs. MEC: Randomized Phase III trial (E2995). Proc. Am. Soc. Hematol., 94 (Suppl. 1): 1703a, 1999.
17. Baer, M. R., George, S. L., Dodge, R. K., Cooke, K., Caligiuri, M. A., Powell, B. L., Kolitz, J. E., Schiffer, C. A., and Larson, R. A. Phase III study of PSC-833 modulation of multi-drug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients ≥60 years (CALGB 9720). Proc. Am. Soc. Hematol., 94 (Suppl. 1): 1704a, 1999.
18. Dantzig, A. H., Shepard, R. L., Law, K. L., Tabas, L., Pratt, S., Gillespie, J. S., Binkley, S. N., Kuhfeld, M. T., Starling, J. J., and Wrighton, S. A. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J. Pharmacol. Exp. Ther., 290: 854-862, 1999.
19. Cui, Y., Konig, J., Buchholz, J. K., Spring, H., Leier, I., and Keppler, D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol., 55: 929-937, 1999.
20. Keppler, D., Kamisako, T., Leier, I., Cui, Y., Nies, A. T., Tsujii, H., and Konig, J. Localization, substrate specificity, and drug resistance conferred by conjugate export pumps of the MRP family. Adv. Enzyme Regul., 40: 339-349, 2000.
21. Von Hoff, D. D., Layard, M. W., Basa, P., Davis, H. L., Jr., Von Hoff, A. L., Rozencweig, M., and Muggia, F. M. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med., 91: 710-717, 1979.
22. Schinkel, A. H., Wagenaar, E., Mol, C. A., and van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Investig., 97: 2517-2524, 1996.
23. Patnaik, A., Warner, E., Michael, M., Egorin, M. J., Moore, M. J., Siu, L. L., Fracasso, P. M., Rivkin, S., Kerr, I., Litchman, M., and Oza, A. M. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. J. Clin. Oncol., 18: 3677-3689, 2000.
24. Ehlhardt, W. J., Woodland, J. M., Baughman, T. M., Vandenbranden, M., Wrighton, S. A., Kroin, J. S., Norman, B. H., and Maple, S. R. Liquid chromatography/nuclear magnetic resonance spectroscopy and liquid chromatography/mass spectrometry identification of novel metabolites of the multidrug resistance modulator LY335979 in rat bile and human liver microsomal incubations. Drug Metab. Dispos., 26: 42-51, 1998.